Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on July 30, 2020, covering events occurring on July 27, 2020. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California.
Key Financial Metrics and Obligations
The filing details a specific financing event rather than comprehensive financial statements. Key metrics include:
- New Debt: AgeX borrowed an additional $1.0 million under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due on March 30, 2023.
- Equity Issuance: In connection with loan draws, the company issued or became obligated to issue 28,500 shares of common stock.
- Warrants Issued: Warrants to purchase 375,939 shares were issued on July 27, 2020, with an exercise price of $1.330 and an expiration date of July 26, 2023.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt balance, or liquidity ratios as of the reporting date.
Material Changes and Contract Amendments
On July 27, 2020, AgeX amended its New Loan Agreement with Juvenescence to facilitate the $1.0 million draw. Material changes to the agreement include:
- Waiver of Collateral Requirements: Provisions requiring the execution of a Security Agreement and related collateral pledges for this specific draw were waived.
- Waiver of Guarantees: Requirements for certain subsidiaries to guarantee AgeX's obligations were waived for this draw.
- Future Conditions: Juvenescence retains the discretion to condition any advances subsequent to this draw on the receipt of the previously waived collateral agreements and guarantees.
- Listing Compliance: The agreement was amended to limit the number of shares issuable upon conversion or warrant exercise to comply with NYSE American listing requirements.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors.
Events of Default: The lender may declare the loan immediately due and payable if an Event of Default occurs and remains uncured for 10 business days. Defined events include:
- Failure to pay amounts due or perform obligations.
- Default on other indebtedness exceeding $100,000 or failure to pay indebtedness exceeding $25,000 when due.
- Insolvency, liquidation, or inability to pay debts as they become due.
- Material adverse change in financial condition affecting the ability to perform obligations.
- Disposal of a material part of assets by AgeX or guarantor subsidiaries without approval.
- Invalidity of security interests or loss of collateral.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement as of July 27, 2020.
- Confirm the current status of the Security Agreement and whether collateral has been pledged for future draws.
- Review the company's cash position to assess liquidity relative to the March 30, 2023 repayment date.
- Check for any subsequent filings regarding the exercise of the 375,939 warrants issued on July 27, 2020.
- Monitor compliance with NYSE American listing requirements regarding share issuance limits.